Subgroup analysis of patients with HER2-negative metastatic breast cancer in the second-line setting from a phase 3, open-label, randomized study of eribulin mesilate versus capecitabine
This post hoc subgroup analysis of a large phase 3 study compared the efficacy and safety of eribulin versus capecitabine in patients with human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer who received second-line treatment. In the phase 3 study, women with advanced/m...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
4 January 2018
|
| In: |
Breast cancer
Year: 2018, Jahrgang: 25, Heft: 3, Pages: 370-374 |
| ISSN: | 1880-4233 |
| DOI: | 10.1007/s12282-017-0826-4 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1007/s12282-017-0826-4 Verlag, lizenzpflichtig, Volltext: https://link.springer.com/article/10.1007/s12282-017-0826-4 
|
| Verfasserangaben: | Xavier Pivot, Seock Ah Im, Matthew Guo, Frederik Marmé |
| Zusammenfassung: | This post hoc subgroup analysis of a large phase 3 study compared the efficacy and safety of eribulin versus capecitabine in patients with human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer who received second-line treatment. In the phase 3 study, women with advanced/metastatic breast cancer and ≤ 3 prior chemotherapies were randomized 1:1 to eribulin mesilate 1.4 mg/m2 intravenously on days 1 and 8, or twice-daily oral capecitabine 1.25 g/m2 on days 1-14 (21-day cycles). This analysis included 392 patients. Median overall survival was longer in patients receiving eribulin compared with capecitabine (16.1 vs 13.5 months, respectively; HR 0.77, P = 0.026). Median progression-free survival and response rates were similar between arms. Both treatments had manageable safety profiles. |
|---|---|
| Beschreibung: | Gesehen am 23.04.2020 |
| Beschreibung: | Online Resource |
| ISSN: | 1880-4233 |
| DOI: | 10.1007/s12282-017-0826-4 |